MSB 2.98% $1.47 mesoblast limited

fda study unprecedented !, page-6

  1. 10,843 Posts.
    lightbulb Created with Sketch. 4
    Down 60% now and falling.

    Athersys is/was a competitor to MSB suite of treatments I think
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.